EP1618187A2 - Multiply-primed amplification of nucleic acid sequences - Google Patents
Multiply-primed amplification of nucleic acid sequencesInfo
- Publication number
- EP1618187A2 EP1618187A2 EP04760456A EP04760456A EP1618187A2 EP 1618187 A2 EP1618187 A2 EP 1618187A2 EP 04760456 A EP04760456 A EP 04760456A EP 04760456 A EP04760456 A EP 04760456A EP 1618187 A2 EP1618187 A2 EP 1618187A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- dna
- amplification
- amplified
- modified
- sequencing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000003321 amplification Effects 0.000 title claims abstract description 118
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 118
- 150000007523 nucleic acids Chemical group 0.000 title claims description 35
- 238000000034 method Methods 0.000 claims abstract description 116
- 230000008569 process Effects 0.000 claims abstract description 26
- 238000012163 sequencing technique Methods 0.000 claims abstract description 22
- 238000009396 hybridization Methods 0.000 claims abstract description 21
- 238000001712 DNA sequencing Methods 0.000 claims abstract description 19
- 238000004458 analytical method Methods 0.000 claims abstract description 16
- 239000003155 DNA primer Substances 0.000 claims abstract description 11
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 7
- 230000037429 base substitution Effects 0.000 claims abstract 2
- 239000013615 primer Substances 0.000 claims description 73
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 54
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 54
- 125000003729 nucleotide group Chemical group 0.000 claims description 53
- UFJPAQSLHAGEBL-RRKCRQDMSA-N dITP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1 UFJPAQSLHAGEBL-RRKCRQDMSA-N 0.000 claims description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 239000001226 triphosphate Substances 0.000 claims description 20
- 235000011178 triphosphate Nutrition 0.000 claims description 19
- -1 nucleoside triphosphates Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 238000001962 electrophoresis Methods 0.000 claims description 14
- 238000002844 melting Methods 0.000 claims description 13
- 230000008018 melting Effects 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 13
- 108091034117 Oligonucleotide Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 11
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 10
- 238000010348 incorporation Methods 0.000 claims description 7
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 claims description 5
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 3
- AZJLCKAEZFNJDI-DJLDLDEBSA-N [[(2r,3s,5r)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 AZJLCKAEZFNJDI-DJLDLDEBSA-N 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 102220499813 Carbonic anhydrase 2_N62D_mutation Human genes 0.000 claims 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 abstract description 154
- 102000053602 DNA Human genes 0.000 abstract description 20
- 238000001514 detection method Methods 0.000 abstract description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 9
- 108020004682 Single-Stranded DNA Proteins 0.000 abstract description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 abstract 2
- 239000005547 deoxyribonucleotide Substances 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 238000013467 fragmentation Methods 0.000 abstract 1
- 238000006062 fragmentation reaction Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 47
- 239000002773 nucleotide Substances 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 31
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 108060002716 Exonuclease Proteins 0.000 description 16
- 102000013165 exonuclease Human genes 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 238000006073 displacement reaction Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 108020004638 Circular DNA Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000005096 rolling process Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 241001515965 unidentified phage Species 0.000 description 6
- 230000006820 DNA synthesis Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 230000037452 priming Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000489996 Thermoplasma volcanium Species 0.000 description 4
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 4
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102220550417 Dihydropyrimidinase-related protein 2_N62H_mutation Human genes 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000589499 Thermus thermophilus Species 0.000 description 2
- 241001061127 Thione Species 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003271 compound fluorescence assay Methods 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 239000005546 dideoxynucleotide Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 108010068698 spleen exonuclease Proteins 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108700015125 Adenovirus DBP Proteins 0.000 description 1
- 101150062763 BMRF1 gene Proteins 0.000 description 1
- 241000322342 Bacillus phage M2 Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 101150026402 DBP gene Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101710134178 DNA polymerase processivity factor BMRF1 Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 102220567511 Dihydropyrimidinase-related protein 2_D12A_mutation Human genes 0.000 description 1
- 102220550419 Dihydropyrimidinase-related protein 2_D66A_mutation Human genes 0.000 description 1
- 102220550448 Dihydropyrimidinase-related protein 2_E14A_mutation Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102220513115 Serine/threonine-protein kinase TAO1_D169A_mutation Human genes 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000193447 Thermoanaerobacter thermohydrosulfuricus Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 108700014590 single-stranded DNA binding proteins Proteins 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Definitions
- the present invention relates to improved processes for DNA amplification by multiply primed rolling circle and multiple displacement amplification so as to provide modified products.
- the amplification process is carried out using various nucleotide analogs giving the product improved properties, particularly for further analysis by sequencing or other methods.
- PCR polymerase chain reaction
- LCR ligase chain reaction
- 3SR self-sustained sequence replication
- NASBA nucleic acid sequence based amplification
- SDA strand displacement amplification
- Q. ⁇ . replicase (Bir enmeyer and Mushahwar, J. Virological Methods, 35:1 17- 126 (1991); Landegren, Trends Genetics, 9:199-202 (1993)).
- LRCA linear rolling circle amplification
- ATC amplification target circle
- ERCA exponential RCA
- HRCA Exponential rolling circle amplification
- ERCA is limited to the use of just a single primer PI annealed to the circular DNA target molecule, to the need to know the specific DNA sequence for the primer PI , and for the need of the circular DNA target molecule to be a single- stranded DNA circle.
- the methods of the US6323009 patent avoid such disadvantages by employing procedures that improve on the sensitivity of linear rolling circle amplification by using multiple primers for the amplification of individual target circles.
- the MPA method has the advantage of generating multiple tandem-sequence DNA (TS-DNA) copies from each circular target DNA molecule.
- TS-DNA tandem-sequence DNA
- MPA has the advantages that in some cases the sequence of the circular target DNA molecule may be unknown while the circular target DNA molecule may be single-stranded (ssDNA) or double-stranded (dsDNA or duplex DNA).
- MPA method Another advantage of the MPA method is that the amplification of single-stranded or double-stranded circular target DNA molecules may be carried out isothermally and/or at ambient temperatures. Other advantages include being highly useful in new applications of rolling circle amplification, low cost, sensitivity to low concentration of target circle, flexibility, especially in the use of detection reagents, and low risk of contamination.
- the MPA method can improve on the yield of amplified product DNA by using multiple primers that are resistant to degradation by exonuclease activity that may be present in the reaction. This has the advantage of permitting the primers to persist in reactions that contain an exonuclease activity and that may be carried out for long incubation periods. The persistence of primers allows new priming events to occur for the entire incubation time of the reaction, which is one of the hallmarks of ERCA and has the advantage of increasing the yield of amplified DNA.
- the MPA method allows for the first time "in vitro cloning", i.e. without the need for cloning into an organism, of known or unknown target DNAs enclosed in circles.
- a padlock probe may be used to copy the target sequence into a circle by the gap fill-in method (Lizardi, P. M. et al. Nature Genetics, 19,225-231 (1998)).
- target sequences can be copied or inserted into circular ssDNA or dsDNA by many other commonly used methods.
- the MPA amplification overcomes the need to generate amplified yields of the DNA by cloning in organisms.
- the MPA method is an improvement over LRCA in allowing increased rate of synthesis and yield. This results from the multiple primer sites for DNA polymerase extension. Random primer MPA also has the benefit of generating double stranded products. This is because the linear ssDNA products generated by copying of the circular template will themselves be converted to duplex form by random priming of DNA synthesis. Double stranded DNA product is advantageous in allowing for DNA sequencing of either strand and for restriction endonuclease digestion and other methods used in cloning, labeling, and detection. It is also expected that strand-displacement DNA synthesis may occur during the MPA method resulting in an exponential amplification. This is an improvement over conventional ERCA, also termed HRCA (Lizardi et al. (1998)) in allowing for the ability to exponentially amplify very large linear or circular DNA targets. The amplification of large circular DNA, including bacterial artificial chromosomes (BACs), has been reduced to practice using the MPA method.
- BACs bacterial artificial
- the MPA method rapidly amplifies every sample of DNA used with it, the double-stranded product has all the same sequences as the original sample. Except for the fact that it contains tandemly-repeated copies of the DNA with numerous initiation (priming) sites, the physical properties of the product DNA are much like those of the starting template.
- the object of the invention to provide a new method of amplification that can be used for any DNA even if the sequence is not known, can provide for complete or near-complete substitution of nucleotide analogs for the usual nucleotides, and which can be carried out isothermally at temperatures down to 0°C.
- This and other objectives were met by the present invention, which employs modified MPA (mMPA) using non-natural nucleotides to prepare DNA that may be used for sequenceing or other downstream analysis purposes.
- mMPA modified MPA
- the present invention relates to a process for the enhanced amplification of
- this aspect of the invention employs multiple primers (specific or random, exonuclease- sensitive or exonuclease-resistant) annealed to the target DNA molecules to increase the yield of amplified product from RCA.
- Multiple primers anneal to multiple locations on the target DNA and extension by polymerase is initiated from each location. In this way multiple extensions are achieved simultaneously from the target DNA.
- the extension process is carried out in the presence of one or more nucleotide analogs, optionally in the presence of all four normal nucleotides.
- the nucleotide analogs confer unusual properties to the product DNA without changing its sequence content.
- primers are used in several different ways. It is achieved by using two or more specific primers that anneal to different sequences on the target DNA, or by having one given primer anneal to a sequence repeated at two or more separate locations on the target DNA, or by using random or degenerate primers, which can anneal to many locations on the target DNA.
- dITP is substituted for some or all of the dGTP in the amplification reaction mixture.
- the addition of the dITP does not deleteriously affect the MPA reaction, producing significant quantities of amplified nucleic acid.
- the deoxyribonucleoside-5'-triphosphates (dNTPs) used in the MPA reaction may be substituted by their analogs that upon incorporation reduce the Tm of the amplified product.
- dGTP may be substituted by 7- deaza-dGTP (Seela, US 4,804,748 and US 5,480,980), 7-deaza-dITP, 7-substituted-7- deaza-dlTP or dGTP (Fuller, McDougall & Kumar, GB 2323357A).
- dATP may be substituted by 7-deaza-dATP or related analogs
- dCTP may be substituted by N4-alkyl-dCTP (Nucleic Acids Res.1993, 21, 2709-14), 5-alkyl-dCTP or related analogs
- dTTP may be substituted by 5-substituted -dTTP.
- the primers for MPA contain nucleotides, including all types of modified nucleotides, which may serve to make the primers resistant to enzyme degradation.
- Enzyme degradation may be caused by a specific exonuclease such as the 3'-5' exonuclease activity associated with DNA polymerase or by a nonspecific, contaminating exonuclease.
- FIG. 1 shows an electropherogram of a DNA sequencing reaction using DYEnamic ET-terminator kit (Amersham Biosciences Inc.) with DNA amplified by standard MPA from 2 ng of pNASS ⁇ DNA as the template and 5 pmol of MHXP primer.
- FIG. 2 is an electropherogram of a DNA sequencing reaction using DYEnamic ET- terminator kit (Amersham Biosciences Inc.) with DNA amplified by modified
- FIG. 3 is an electropherogram of a DNA sequencing reaction using DYEnamic ET- terminator kit (Amersham Biosciences Inc.) with DNA amplified by modified MPA(with 0.8 mM dITP and 0.05 mM dGTP) from 2 ng of pNASS ⁇ DNA as the template and 5 pmol of MHXP primer.
- FIG. 4 is an electropherogram of a DNA sequencing reaction using DYEnamic ET- terminator kit (Amersham Biosciences Inc.) with DNA amplified by standard MPA from 1 ⁇ l glycerol stock of a random library of T. Volcanium DNA as the template. Reactions were cycled at normal temperature (30 times at 95°C, 20 seconds, 50°C, 30 seconds and 60°C, 60 seconds).
- FIG. 5 is an electropherogram of a DNA sequencing reaction using DYEnamic ET- terminator kit (Amersham Biosciences Inc.) with DNA amplified by standard MPA from 1 ⁇ l glycerol stock of a random library of T. Volcanism DNA as the template. Reactions were cycled at low temperature (30 times at 82°C, 20 seconds, 40°C, 30 seconds and 50°C, 60 seconds)
- FIG. 6 is an electropherogram of a DNA sequencing reaction using DYEnamic ET- terminator kit (Amersham Biosciences Inc.) with DNA amplified by modified MPA(with 0.8 mM dITP and 0.05 mM dGTP from 1 ⁇ l glycerol stock of a random library of T. Volcanium DNA as the template. Reactions were cycled at normal temperature (30 times at 95°C, 20 seconds, 50°C, 30 seconds and 60°C, 60 seconds)
- FIG. 7 is an electropherogram of a DNA sequencing reaction using DYEnamic ET- terminator kit (Amersham Biosciences Inc.) with DNA amplified by modified MPA (with 0.8 mM dITP and 0.05 mM dGTP from 1 ⁇ l glycerol stock of a random library of T. Volcanium DNA as the template. Reactions were cycled at low temperature (30 times at 82°C, 20 seconds, 40°C, 30 seconds and 50°C, 60 seconds)
- the present invention pertains to analysis of DNA and in particular to analyses that depend on the sequence of DNA, often used for determining genotype as well as original sequence information. It also pertains to amplification of DNA sequences.
- Amplification means synthesis of new strands of DNA which have complimentary sequence to the original, preserving the original sequence information. While some amplification methods such as polymerase chain reaction (PCR) are highly specific and yield amplified products of defined length, others are general, amplifying all the DNA sequences present in a sample yielding products that vary in length yet still contain the original sequence information.
- PCR polymerase chain reaction
- MPA as described in US6323009.
- This invention also pertains to DNA sequencing, which is defined as a method for determining the nucleotide base sequence of a DNA molecule comprising the steps of incubating the nucleic acid molecule with an oligonucleotide primer, a plurality of deoxynucleoside triphosphates, at least one chain terminating agent, and a DNA polymerase under conditions in which the primer is extended until the chain terminating agent is incorporated.
- the products are separated according to size, detected and whereby at least a part of the nucleotide base sequence of the original DNA molecule can be determined (see, for example US5639608).
- a more advantageous sequencing method is cycle sequencing with dideoxynucleotide terminators.
- Cycle sequencing involves multiple rounds of DNA synthesis carried out from the same template using an oligonucleotides primer. The newly synthesized strand is removed from the template strand after each synthesis cycle by heat denaturation; this amplifies the number of strands produced in the sequencing process and allows much smaller amounts of DNA template to be sequenced (US5614365).
- a particularly useful way of performing cycle sequencing is with thermally stable DNA polymerase and fluorescent-labeled dideoxynucleotide terminators (for example US5366860). This, most popular method of sequencing typically makes use of dITP to eliminate electrophoresis artifacts, and four distinct fluorescent labels for the four nucleotide bases.
- the polymerase chain reaction is defined as a process for amplifying at least one specific nucleic acid sequence contained in a nucleic acid or a mixture of nucleic acids wherein each nucleic acid consists of two separate complementary strands.
- the strands are combined with two oligonucleotide primers, for the specific sequence being amplified, under conditions such that the extension product synthesized from one primer, when it is separated from its complement, can serve as a template for synthesis of the extension product of the other primer.
- the primers are extended using DNA polymerase then the extension products denatured by heating from the templates on which they were synthesized to produce single-stranded molecules.
- the single-stranded molecules generated anneal with the primers and are again extended by DNA polymerase.
- the process is repeated one or more times resulting in exponential amplification of the sequences "between" the priming sites US4683202.
- Single Strand Confirmation Polymorphism is a process that can be used for the detection of polymorphisms (Orita et al, PNAS 86(8) April 1989 2766- 70; Lessa-et al. Mol Ecol 2(2) p. 119-29 April 1993). Essentially, labeled, denatured fragments of DNA are applied to a non-denaturing electrophoresis gel. If polymorphisms (sequence variants) exist in the fragment, more than one band may be observed on the gel because the conformation of the single-stranded fragments differ with different sequences.
- Hybridization is a technique of using the natural tendency for nucleic acids to bind specifically to other nucleic acid strands with complimentary sequence.
- Virtually all molecular biology experiments feature hybridization, for example the sequencing primer hybridizes with the sequencing template.
- the PCR primers hybridize with the desired template strands.
- More general hybridization experiments may involve hybridization of an immobilized nucleic acid with a soluble, labeled or tagged nucleic acid in techniques variously called “Southern” hybridizations (Southern, E., J Mol Biol. 1975 98(3):503-17), “Northern” hybridizations (Alwine et. Al, Proc Natl Acad Sci U S A.
- the invention relates to the use of multiple primers in nucleic acid sequence amplification as a means of greatly amplifying DNA synthesis and providing greatly increased amounts of DNA for detection of specific nucleic acid sequences contained in, for example, a target DNA. While previous methods have often employed targets of substantial complexity, the present invention utilizes relatively simple targets, such as simple plasmid, cos id and bacterial artificial chromosome (BAC) targets.
- the target DNA useful in the present invention also includes linear DNA, even high molecular weight linear DNA.
- the present invention further relates to the discovery that the replacement of some or all of the normal nucleotides (e.g. dGTP) within the amplification reaction mix by modified nucleotide analogs (e.g. dITP, 2'-deoxy Inosine triphosphate) produces an amplification product with significantly enhanced properties, including ability to be sequenced and ability to hybridize at altered temperature.
- normal nucleotides e.g. dGTP
- modified nucleotide analogs e.g. dITP, 2'-deoxy Inosine triphosphate
- substantially complex target DNA molecules for example, a nucleic acid, including either DNA or RNA, whose presence in a sample is to be detected or whose sequence is to be amplified, such as for use in subsequent methods or procedures, or whose presence in said sample determines the identity of one or more other nucleic acids whose sequence(s) is/are to be amplified
- the present invention relates to the amplification of all the sequences present in the target, with no attempts at any reduction in sequence complexity.
- one can provide a premix such as in the form of a kit, comprising a polymerase, even including more than one polymerase, nuclease- protected oligonucleotide primers, such as random-sequence hexamers, the required nucleoside triphosphates, an appropriate buffer, optionally a pyrophosphatase, and other potentially desirable components, either with each such component in a separate vial or mixed together in different combinations so as to form a total of one, two, three, or more separate vials and, for example, a blank or buffer vial for suspending an intended target nucleic acid for use in the amplification process.
- a premix such as in the form of a kit, comprising a polymerase, even including more than one polymerase, nuclease- protected oligonucleotide primers, such as random-sequence hexamers, the required nucleoside triphosphates, an appropriate buffer, optionally a pyro
- One embodiment of the present invention comprises a kit for amplifying DNA sequences comprising nuclease-resistant random primers, a DNA polymerase and the four deoxyribonucleoside triphosphates (dNTPs), .
- said DNA polymerase has 3'-5' exonuclease activity.
- said DNA polymerase is ⁇ 29 DNA polymerase.
- at least one of the normal dNTPs is replaced, in whole or in part, by an analog whose presence in the product DNA confers some advantageous property to said product DNA or to subsequent processes such as sequence-dependent analyses.
- a sample of nucleic acid such as a DNA
- a buffer such as TE buffer
- a buffer such as TE buffer
- the components recited above either sequentially or by adding such components as the aforementioned premix with the conditions of temperature, pH and the like subsequently adjusted, for example by maintaining such combination at 10°C.
- the conditions used in carrying out the processes disclosed according to the present invention may vary during any given application.
- the primers and target DNA may be added under conditions that promote hybridization and the DNA polymerase and nucleoside triphosphates added under different conditions that promote amplification without causing denaturation of the primer-target complexes that act as substrates for the polymerase or polymerases.
- the present invention relates to a process as described herein wherein the target DNA binds to, or hybridizes to, at least 3, 4, 5, even 10, or more primer oligonucleotides, each said primer producing, under appropriate conditions, a separate tandem sequence DNA molecule.
- TS-DNAs tandem sequence DNAs
- the TS-DNA products will all have the same sequence as the target DNA, regardless of the sequence of the primers and the nucleotide content of the TS-DNA product will be determined by the mixture of nucleotides or nucleotide analogs used for the amplification subject to the selective power of the DNA polymerase or polymerases used in the amplification process.
- the oligonucleotide primers useful in the processes of amplification can be of any desired length.
- such primers may be of a length of from at least 2 to about 30 to 50 nucleotides long, preferably about 2 to about 35 nucleotides in length, most preferably about 5 to about 10 nucleotides in length, with hexamers and octamers being specifically preferred embodiments.
- Such multiple primers as are used herein may equally be specific only, or random-sequence only, or a mixture of both, with random primers being especially useful and convenient to form and use.
- Amplification target DNA useful in the processes of the present invention are DNA or RNA molecules, either single or double stranded, including DNA-RNA hybrid molecules generally containing between 40 to 10,000 nucleotides. However, it is expected that there will be no upper limit to the size of the target, particularly when using short, random-sequence primers. Where the target is a duplex, such numbers are intended to refer to base pairs rather than individual nucleotide residues.
- the target templates useful in the processes disclosed herein may have functionally different portions, or segments, making them particularly useful for different purposes. At least two such portions will be complementary to one or more oligonucleotide primers and, when present, are referred to as a primer complementary portions or sites.
- Amplification targets useful in the present invention include, for example, those derived directly from such sources as a bacterial colony, a bacteriophage, a virus plaque, a yeast colony, a baculovirus plaque, as well as transiently transfected eukaryotic cells. Such sources may or may not be lysed prior to obtaining the targets. Where such sources have been lysed, such lysis is commonly achieved by a number of means, including where the lysing agent is heat, an enzyme, the latter including, but not limited to, enzymes such as lysozyme, helicase, glucylase, and zymolyase, or such lysing agent may be an organic solvent.
- amplification occurs with each primer, thereby forming a concatemer of tandem repeats (i.e., a TS-DNA) of segments complementary to the primary ATC (or ATC) being replicated by each primer.
- a TS-DNA concatemer of tandem repeats
- many such TS-DNAs are formed, one from each primer, to provide greatly increased amplification of the corresponding sequence since the nucleotide sequence, or structure, of the product depends only on the sequence of the template and not on the sequences of the oligonucleotide primers, whether the latter are random or specific or a mixture of both.
- the amplification method used in the present invention is distinct from published modified PCR methods (see for example Cheung, V. G. and Nelson, S. F. Proc. Natl. Acad. Sci. USA, 93, 14676-14679 (1996); and Zhang, L. et al., Proc. Natl. Acad. Sci. USA, 89, 5847-5851 (1992)) by facilitating use of random or multiple primers in an amplification of linear DNA target with a DNA polymerase, such as ⁇ 29 DNA polymerase as a preferred enzyme for this reaction, along with exonuclease- resistant primers (as described below).
- a DNA polymerase such as ⁇ 29 DNA polymerase as a preferred enzyme for this reaction
- the present invention includes a method for the amplification of linear DNA targets, including high molecular weight DNAs, as well as genomic and cDNAs, that takes advantage of the characteristics of ⁇ 29 DNA polymerase and the exonuclease-resistant primers that are compatible with the 3'-5' exonuclease activity associated with ⁇ 29 DNA polymerase and wherein said linear DNA target may be used instead of or in addition to circular DNA.
- duplex circles are employed, amplification will commonly occur from both strands as templates. Simultaneous amplification of both circles may or may not be desirable. In cases where the duplex circles are to be further employed in reactions designed to sequence the DNA of said circles, amplification of both strands is a desirable feature and so the duplex circles can be directly employed without further processing (except for formation of a nick if needed). However, for other uses, where co-temporal amplification of both strands is not a desired feature, it is well within the skill of those in the art to denature and separate the strands prior to amplification by the processes of the present invention or, alternatively, to employ multiple specific primers that contain sequences complementary to only one of the two strands of the duplex circular template. No doubt other useful strategies will immediately occur to those of skill in the art and need not be further described herein.
- the amplification step of the present invention works well with any number of standard detection schemes, such as where special deoxynucleoside triphosphates (dNTPs) are utilized that make it easier to do quantitative measurements.
- dNTPs deoxynucleoside triphosphates
- the most common example is where such nucleotide substrates are radiolabeled or have attached thereto some other type of label, such as a fluorescent label or the like. These are typically used in trace amounts so as to minimally disturb the composition of the product DNA.
- the methods that can be employed in such circumstances are many and the techniques involved are standard and well known to those skilled in the art.
- detection labels include any molecule that can be associated with amplified nucleic acid, directly or indirectly, and which results in a measurable, detectable signal, either directly or indirectly.
- Many such labels for incorporation into nucleic acids or coupling to nucleic acid probes are known to those of skill in the art.
- General examples include radioactive isotopes, fluorescent molecules, phosphorescent molecules, enzymes, antibodies, and ligands.
- the use of such trace amounts of labeled or tagged nucleotides is considered distinct from the use of sufficient quantities of nucleotide analogs to significantly alter the physical properties of the product DNA sush as changing the melting temperature of the product DNA by as much as 1°C to as much as 20°C or more.
- fluorescent labels examples include Cy Dyes such as Cy2, Cy3,
- fluorescent labels include fluorescein, 5,6- carboxymethyl fluorescein, Texas red, nitrobenz-2-oxa-l,3-diazol-4-yl (NBD), coumarin, dansyl chloride, and rhodamine.
- Preferred fluorescent labels are fluorescein (5-carboxyfluorescein-N-hydroxysuccinimide ester) and rhodamine (5,6-tetramethyl rhodamine). These can be obtained from a variety of commercial sources, including Molecular Probes, Eugene, OR and Research Organics, Cleveland, Ohio.
- Labeled nucleotides are a preferred form of detection label since they can be directly incorporated into the products of amplification during synthesis.
- detection labels that can be incorporated into amplified DNA include nucleotide analogs such as BrdUrd (Hoy and Schimke, Mutation Research, 290:217-230 (1993)), BrUTP (Wansick et al., J. Cell Biology, 122:283-293 (1993)) and nucleotides modified with biotin (Langer et al., Proc. Natl. Acad. Sci. USA, 78:6633 (1981)) or with suitable haptens such as digoxygenin (Kerkhof, Anal.
- Suitable fluorescence-labeled nucleotides are Fluorescein-isothiocyanate- dUTP, Cyanine-3-dUTP and Cyanine-5-dUTP (Yu et al., Nucleic Acids Res., 22:3226-3232 (1994)).
- a preferred nucleotide analog detection label for DNA is BrdUrd (BUDR triphosphate, Sigma), and a preferred nucleotide analog detection label is Biotin- 16-uridine-5 '-triphosphate (Biotin- 16-dUTP, Boehringher Mannheim). Radiolabels are especially useful for the amplification methods disclosed herein.
- dNTPs may incorporate a readily detectable moiety, such as a fluorescent label as described herein.
- the methods of the present invention provide high amplification rates due to multiple priming events being induced on molecules that are targets for amplification.
- the rate and extent of amplification is not limited to that accomplished by a single DNA polymerase copying the DNA circle. Instead, multiple DNA polymerases are induced to copy each template circle simultaneously, each one initiating from one of the primers. It is this feature that provides a unique advantage of the present method and compensates for decreased synthesis rate caused by the use of nucleotide analogs such as dITP in place of dGTP.
- Exonuclease-resistant primers useful in the methods disclosed herein may include modified nucleotides to make them resistant to exonuclease digestion.
- a primer may possess one, two, three or four phosphorothioate linkages between nucleotides at the 3' end of the primer.
- the amplification step relates to processes wherein the primers contain at least one nucleotide that makes the primer resistant to degradation, commonly by an enzyme, especially by an exonuclease and most especially by 3 '-5 '-exonuclease activity.
- at least one nucleotide may be a phosphorothioate nucleotide or some modified nucleotide.
- nucleotide is commonly a 3'-terminal nucleotide but the processes of the present invention also relate to embodiments wherein such a nucleotide is located at other than the 3'-terminal position and wherein the 3'-terminal nucleotide of said primer can be removed by 3 '-5 '-exonuclease activity.
- Target templates or oligonucleotide primers to solid supports may be advantageous and can be achieved through means of some molecular species, such as some type of polymer, biological or otherwise, that serves to attach said primer or target template to a solid support.
- Such solid-state substrates useful in the methods of the invention can include any solid material to which oligonucleotides can be coupled.
- Solid-state substrates can have any useful form including thin films or membranes, beads, bottles, dishes, fibers, woven fibers, shaped polymers, particles and microparticles.
- a preferred form for a solid-state substrate is a glass slide or a microtiter dish (for example, the standard 96-well dish).
- Preferred embodiments utilize glass or plastic as the support.
- glass or plastic for additional arrangements, see those described in U.S. Pat. No.5,854,033.
- Oligonucleotides can be coupled to substrates using established coupling methods. For example, suitable attachment methods are described by Pease et al., Proc. Natl. Acad. Sci. USA 91(11):5022-5026 (1994). A preferred method of attaching oligonucleotides to solid- state substrates is described by Guo et al., Nucleic Acids Res. 22:5456-5465 (1994).
- Oligonucleotide primers useful in the present invention can be synthesized using established oligonucleotide synthesis methods. Methods of synthesizing oligonucleotides are well known in the art. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see for example, Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), Wu et al, Methods in Gene Biotechnology (CRC Press, New York, N.Y., 1997), and Recombinant Gene Expression Protocols, in Methods in Molecular Biology, Vol.
- Protein nucleic acid molecules can be made using known methods such as those described by Nielsen et al., Bioconjugate. Chem. 5:3-7 (1994).
- Phosphorothioate triesters can be introduced by oxidizing the intermediate phosphite triester obtained during phosphoramidite chemistry with 3H-1, 2-benzodithiol-3-one 1,1 dioxide.sup.1,2 or Beaucage reagent to generate pentavalent phosphorous in which the phosphorothioate triester exists as a thione.
- the thione formed in this manner is stable to the subsequent oxidation steps necessary to generate internucleotidic phosphodiesters.
- oligonucleotides described herein are designed to be complementary to certain portions of other oligonucleotides or nucleic acids such that hybrids can be formed between them.
- the stability of these hybrids can be calculated using known methods such as those described in Lesnick and Freier, Biochemistry 34:10807-10815 (1995), McGraw et al., Biotechniques 8:674-678 (1990), and Rychlik et al., Nucleic Acids Res. 18:6409-6412 (1990).
- DNA polymerases useful in the isothermal amplification step are referred to herein as amplification DNA polymerases.
- a DNA polymerase be capable of displacing the strand complementary to the template strand, termed strand displacement, and lack a 5' to 3' exonuclease activity. Strand displacement is necessary to result in synthesis of multiple tandem copies of the target template. A 5' to 3' exonuclease activity, if present, might result in the destruction of the synthesized strand. It is also preferred that DNA polymerases for use in the disclosed method are highly processive. The suitability of a DNA polymerase for use in the disclosed method can be readily determined by assessing its ability to carry out amplification.
- Preferred amplification DNA polymerases are bacteriophage .
- ⁇ .29 DNA polymerase U.S. Pat. Nos. 5,198,543 and 5,001,050 to Blanco et al.
- phage M2 DNA polymerase Matsumoto et al., Gene 84:247 (1989)
- phage PRDl DNA polymerase Jung et al., Proc. Natl. Aced. Sci. USA 84:8287 (1987), and Zhu and Ito, Biochim. Biophys. Acta. 1219:267- 276 (1994)
- VENT.TM VENT.
- DNA polymerase (Kong et al., J. Biol. Chem. 268:1965- 1975 (1993)), Klenow fragment of DNA polymerase I (Jacobsen et al., Eur. J. Biochem. 45:623-627 (1974)), T5 DNA polymerase (Chatterjee et al., Gene 97:13-19 (1991)), and T4 DNA polymerase holoenzyme (Kaboord and Benkovic, Curr. Biol. 5:149-157 (1995)). . ⁇ .29 DNA polymerase is most preferred.
- Equally preferred polymerases include native T7 DNA polymerase, Bacillus stearothermophilus (Bst) DNA polymerase, Thermoanaerobacter thermohydrosulfuricus (Tts) DNA polymerase (U.S. Pat. No. 5,744,312), and the DNA polymerases of Thermus aquaticus, Thermus flavus or Thermus thermophilus. Equally preferred are the . ⁇ .29- type DNA polymerases, which are chosen from the DNA polymerases of phages: . ⁇ .29, Cp-1, PRDl, . ⁇ .15, .
- the DNA polymerase is bacteriophage . ⁇ .29 DNA polymerase wherein the multiple primers are resistant to exonuclease activity and the target DNA is linear DNA, especially high molecular weight and/or complex linear DNA, genomic DNA, cDNA.
- Strand displacement during amplification can be facilitated through the use of a strand displacement factor, such as a helicase.
- a strand displacement factor such as a helicase.
- any DNA polymerase that can perform amplification in the presence of a strand displacement factor is suitable for use in the processes of the present invention, even if the DNA polymerase does not perform amplification in the absence of such a factor.
- Strand displacement factors useful in amplification include BMRF1 polymerase accessory subunit (Tsurumi et al., J. Virology 67(12):7648-7653 (1993)), adenovirus DNA-binding protein (Zijderveld and van der Vliet, J.
- the ability of a polymerase to carry out amplificaiton can be determined by testing the polymerase in a rolling circle replication assay such as those described in Fire and Xu, Proc. Natl. Acad: Sci. USA 92:4641-4645 (1995) and in Lizardi (U.S. Pat. No. 5,854,033, e.g., Example 1 therein).
- the target DNA may be, for example, a single stranded bacteriophage DNA or double stranded DNA plasmid or other vector, which is amplified for the purpose of DNA sequencing, cloning or mapping, and/or detection.
- the examples below provide specific protocols but conditions can vary depending on the identity of the DNA to be amplified and analyzed or sequenced.
- the present invention relates to the ability to change the physical properties, particularly the Tm or melting temperature of the product DNA by changing the nucleotides used during amplification.
- amplification of the target template is not strictly required, merely replicating it with changed physical properties would be sufficient for some applications, but for most practical applications where amplification is desirable anyway, we refer to this step as "amplification".
- Some embodiments of this method feature the use of random-sequence hexamer primers added in great excess to target DNA, ⁇ 29 DNA polymerase and the four normal dNTPs (dATP, dCTP, dGTP and dTTP) to produce multiple copies of all the sequences present in the original target sample.
- dNTPs normal dNTPs
- One way of checking that the product is similar to the starting target is to measure the Tm of both the product and the starting target template.
- Another is to use restriction endonucleases to digest the product DNA and the original target DNA and compare the sizes of the digestion products by gel electrophoresis.
- sequence analysis can be performed on both the target and product DNAs.
- the Tm, restriction digest and sequence information clearly indicated that the product DNA is the same as the starting target DNA in the parameters that can usually be measured by these methods.
- the overall molecular size of the product DNA may be much larger than the starting target DNA, its restriction digestion pattern, melting temperature and sequence are the same.
- DNA produced by this amplification method there remained some products that resisted sequence analysis, producing characteristic sequence patterns that stopped at repeat regions. These sequences similarly failed when the DNA was amplified by alternative means such as by growing larger quantities of culture and directly purifying the DNA from the host bacteria without amplification.
- Example 1 present certain preferred embodiments of the instant invention but are not intended to be illustrative of all embodiments. These examples should not be construed as limiting the appended claims and/or the scope of this invention.
- Example 1 present certain preferred embodiments of the instant invention but are not intended to be illustrative of all embodiments. These examples should not be construed as limiting the appended claims and/or the scope of this invention.
- Amplification was carried out starting with 2 ng of double-stranded plasmid DNA (for example pNASS ⁇ DNA from Clonetech; Genbank XXU02433) in a 20 ⁇ l reaction volume containing 50 mM Tris-HCl, pH 8.25, 10 mM MgCl 2 ., 0.01% Tween-20, 75 mM KC1, 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM dCTP and 0.2 mM dGTP, 100 pmoles (200 ng) of random hexamer and 100 ng ⁇ 29 DNA polymerase.
- double-stranded DNA for example pNASS ⁇ DNA from Clonetech; Genbank XXU02433
- the reaction mixture was incubated at 30° C for 16 hours to allow amplification of the DNA, and then incubated at 65° C for 10 minutes to inactivate the polymerase.
- Typical yield is 2-4 ⁇ g of DNA product as measured by fluorescence assay using Picogreen dye (Molecular Probes).
- Plasmid DNA (2 ng pNASS ⁇ ) was amplified in a 20 ⁇ l reaction containing 50 mM Tris-HCl, pH 8.25, 10 mM MgCl 2 , 0.01% Tween-20, 75 mM KC1, 0.2 mM dATP, 0.2 M dTTP, 0.2 mM dCTP and 0.4 mM dITP or 0.8mM dITP and 0.05 mM dGTP, 100 pmoles of random hexamer and 100 ng ⁇ 29 DNA polymerase.
- MHXP primer (specific for pNASS ⁇ DNA) is 5' ATTTCAGGTCCCGGATCCGGTG 3' (SEQ ID NO: 1). 5 ⁇ l of each amplification reaction was transferred to a sequencing reaction mixture containing 5 pmoles of MHXP primer, and 8 ⁇ l of DYEnamic ET terminator premix (Amersham Biosciences) and water to a total volume of 20 ⁇ l.. Reaction mixtures were cycled through 95°C, 20 seconds; 50°C, 30 seconds; and 60°C, 60 seconds, repeated 30 times. Reactions were then held at 4°C until purification and analysis which was performed according to the manufacturer's instructions.
- Modified Multiply Primed Amplification significantly improves the DNA sequencing result for this template.
- T m The melting temperature (T m ) of DNA amplified by Standard or Modified
- DNA (plasmid pNASS ⁇ ) was amplified by Multiply-Primed Amplification with 0.2 mM dGTP (Standard) or 0.4 mM dITP or a mixture of 0.8 mM dITP and 0.05 mM dGTP as described in detail in Example 1. 20 reaction mixtures of 20 ⁇ l each were incubated at 30°C for 16 hours, and then incubated at 65°C for 10 minutes.
- Each batch of 20 reactions was pooled together, precipitated by ethanol and resuspended in 400 ⁇ l of lx SSC buffer (150 mM NaCl, 15 mM Na 3 Citrate).
- the OD at 260 nm was adjusted to be in the range of 0.2 to 0.5 using lx SSC buffer in order to perform T m measurements.
- the OD at 260 nm was measured as temperature changed from 30°C to 98°C using a Lambda 25 UV/Vis Spectrophotometer (Perkin Elmer Inc.).
- the T m of the DNA was determined as the peak in the first derivative of the OD 6 o vs temperature curve which is also approximately the temperature at which 50 % of the total increase in OD 260 is observed.
- the T m of pNASS ⁇ DNA amplified with dGTP is 95°C whereas the T m of DNA amplified with dITP is 69°C and that amplified with the mixture of dITP and dGTP is 75°C.
- Reaction products of Modified Multiply-Primed Amplification can be Cycle Sequenced at Lower Temperatures than Products of Standard Multiply- Primed Amplification (MPA).
- a randomly selected clone from a library of T. Volcanium DNA in pUC 18 was amplified by Standard (dGTP) Multiply-Primed Amplification or modified (a mixure of dITP and dGTP) Multiply-Primed Amplification as described in detail in Example 1. Then sequencing reactions were carried out using 5 pmoles of -40 Universal Ml 3 primer and 8 ⁇ l of DYEnamic ET terminator premix and 5 ⁇ l of the amplified DNA. Reactions were cycled at normal temperatures (30 times at 95°C, 20 seconds, 50°C, 30 seconds and 60°C, 60 seconds) or at low temperatures (30 times at 82°C, 20 seconds, 40°C, 30 seconds and 50°C, 60 seconds).
- DNA amplified by modified multiply-primed amplification has altered activity with Restriction Enzymes
- Double-stranded pUC19 DNA (2 ng, Amersham Biosciences) was amplified by Multiply-Primed Rolling Circle Amplification with dGTP (0.2mM) or dITP (0.4 mM) as described in detail in Example 1. After incubation overnight at 30°C, 10 ⁇ l of each reaction mixture was digested with 5 units of Hindlll for 2 hours at 37°C in a 20 ⁇ l reaction volume containing 10 mM Tris-HCl (pH 8.0), 7 mM MgCl 2 , 60 mM NaCl and 2 ⁇ g bovine serum albumin.
- DNA prepared by modified (dITP) amplification is cut by Hindlll (AAGCTT) (SEQ ID NO: 2) but not by BamHI (GGATCC) (SEQ ID NO: 3). Knowing that some restriction endonucleases tolerate substitution of di for dG (Modrich P, Rubin RA. J Biol Chem. 1977 252 7273-8) but BamHI, in particular, does not (Kang YK et.al Biochem Biophys Res. Comm. 1995 206:997-1002), this suggests that dG is indeed replaced by di in modified amplification products.
- DNA Polymerase variants for Modified Multiply-Primed Amplification 2 ng pUC19 DNA was amplified by Multiply-Primed Amplification with dGTP (0.2 mM) or dITP (0.4 mM) or mixture of dITP (0.8mM) and dGTP(0.5mM) as described in detail in Example 1 using 100 ng of the wild type Phi 29 DNA polymerase and each of the following variants with single amino acid substitutions: N62E, N62D, D12A, E14A, D66A and D169A (Bernad A, Blanco L, Lazaro JM, Martin G, Salas M., Cell 1989 59:219-28 and Esteban JA, Soengas MS, Salas M, Blanco L., J Biol Chem 1994269:31946-54).
- DNA polymerase variants N62E and N62D give about ten-fold higher yield of amplified DNA using dITP only modified amplification than wild-type ⁇ 29. With the mixture of dITP and dGTP, these variants yield about 4-5 fold more product than wild-type ⁇ 29. DNA amplified using these polymerase variants appeared to have similar size distribution as DNA amplified using wild-type polymerase and gave similar results when used as template for DNA sequencing experiments.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46651303P | 2003-04-29 | 2003-04-29 | |
PCT/US2004/013395 WO2004097003A2 (en) | 2003-04-29 | 2004-04-29 | Multiply-primed amplification of nucleic acid sequences |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1618187A2 true EP1618187A2 (en) | 2006-01-25 |
EP1618187A4 EP1618187A4 (en) | 2006-12-20 |
Family
ID=33418390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04760456A Ceased EP1618187A4 (en) | 2003-04-29 | 2004-04-29 | Multiply-primed amplification of nucleic acid sequences |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050239087A1 (en) |
EP (1) | EP1618187A4 (en) |
JP (1) | JP2006525023A (en) |
CA (1) | CA2521520A1 (en) |
WO (1) | WO2004097003A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005314431B2 (en) * | 2004-12-11 | 2011-02-17 | Cytogenix, Inc. | Cell free biosynthesis of high-quality nucleic acid and uses thereof |
JP2007175017A (en) * | 2005-12-28 | 2007-07-12 | Sony Corp | Snp discrimination method and dna chip for snp discrimination |
WO2008151023A2 (en) * | 2007-06-01 | 2008-12-11 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
WO2010048337A2 (en) | 2008-10-22 | 2010-04-29 | Illumina, Inc. | Preservation of information related to genomic dna methylation |
EP2488656B1 (en) * | 2009-10-15 | 2015-06-03 | Ibis Biosciences, Inc. | Multiple displacement amplification |
US20110195457A1 (en) * | 2010-02-09 | 2011-08-11 | General Electric Company | Isothermal amplification of nucleic acid using primers comprising a randomized sequence and specific primers and uses thereof |
JP2016531561A (en) * | 2013-10-01 | 2016-10-13 | テクセル | Detection of rare microbiological nucleic acids |
GB201412316D0 (en) | 2014-07-10 | 2014-08-27 | Momentum Bioscience Ltd | Detecting the absence of micro-organisms |
WO2020221915A1 (en) * | 2019-05-02 | 2020-11-05 | F. Hoffmann-La Roche Ag | UTILIZATION OF dITP FOR PREFERENTIAL/SELECTIVE AMPLIFICATION OF RNA VERSUS DNA TARGETS BASED ON STRAND-SEPARATION TEMPERATURE |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994023055A1 (en) * | 1993-03-30 | 1994-10-13 | United States Biochemical Corporation | Cycle sequencing with non-thermostable dna polymerases |
WO1997003210A1 (en) * | 1995-07-11 | 1997-01-30 | FORFÁS (trading as BIORESEARCH IRELAND) | Glycosylase mediated detection of nucleotide sequences at candidate loci |
WO1999041410A1 (en) * | 1998-02-10 | 1999-08-19 | Yeda Research And Development Co. Ltd. | Methods for dna amplification and sequencing |
EP1167524A1 (en) * | 1999-03-19 | 2002-01-02 | Takara Shuzo Co, Ltd. | Method for amplifying nucleic acid sequence |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198543A (en) * | 1989-03-24 | 1993-03-30 | Consejo Superior Investigaciones Cientificas | PHI29 DNA polymerase |
US5846717A (en) * | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
GB2323357B (en) * | 1997-03-20 | 1999-09-29 | Amersham Pharm Biotech Inc | Derivatives of 7-deaza-2-deoxy-guanosine-5'-triphosphate, preparation and use thereof |
US6046039A (en) * | 1998-08-19 | 2000-04-04 | Battelle Memorial Institute | Methods for producing partially digested restriction DNA fragments and for producing a partially modified PCR product |
JP3883476B2 (en) * | 1999-03-19 | 2007-02-21 | タカラバイオ株式会社 | Nucleic acid sequence amplification method |
DK1218542T3 (en) * | 1999-09-13 | 2004-08-02 | Nugen Technologies Inc | Methods and compositions for linear isothermal amplification of polynucleotide sequences |
US6323009B1 (en) * | 2000-06-28 | 2001-11-27 | Molecular Staging, Inc. | Multiply-primed amplification of nucleic acid sequences |
ATE421989T1 (en) * | 2000-12-01 | 2009-02-15 | Cornell Res Foundation Inc | DETECTION OF NUCLEIC ACID DIFFERENCES USING A COMBINATION OF ENDONUCLEASE CLEAVAGE AND LIGATION REACTIONS |
-
2004
- 2004-04-29 JP JP2006514168A patent/JP2006525023A/en active Pending
- 2004-04-29 EP EP04760456A patent/EP1618187A4/en not_active Ceased
- 2004-04-29 WO PCT/US2004/013395 patent/WO2004097003A2/en active Application Filing
- 2004-04-29 CA CA002521520A patent/CA2521520A1/en not_active Abandoned
- 2004-04-29 US US10/835,140 patent/US20050239087A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994023055A1 (en) * | 1993-03-30 | 1994-10-13 | United States Biochemical Corporation | Cycle sequencing with non-thermostable dna polymerases |
WO1997003210A1 (en) * | 1995-07-11 | 1997-01-30 | FORFÁS (trading as BIORESEARCH IRELAND) | Glycosylase mediated detection of nucleotide sequences at candidate loci |
WO1999041410A1 (en) * | 1998-02-10 | 1999-08-19 | Yeda Research And Development Co. Ltd. | Methods for dna amplification and sequencing |
EP1167524A1 (en) * | 1999-03-19 | 2002-01-02 | Takara Shuzo Co, Ltd. | Method for amplifying nucleic acid sequence |
Non-Patent Citations (5)
Title |
---|
DIERICK H ET AL: "INCORPORATION OF DITP OR 7-DEAZA DGTP DURING PCR IMPROVES SEQUENCING OF THE PRODUCT" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 21, no. 18, 1993, pages 4427-4428, XP002911667 ISSN: 0305-1048 * |
LI S ET AL: "ELIMINATION OF BAND COMPRESSION IN SEQUENCING GELS BY THE USE OF N4-METHYL-2'-DEOXYCYTIDINE 5'-TRIPHOSPHATE" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 21, no. 11, 1993, pages 2709-2714, XP002905757 ISSN: 0305-1048 * |
MCDOUGALL M G ET AL: "Analogs of guanine nucleoside triphosphates for sequencing applications." NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS. 2001 APR-JUL, vol. 20, no. 4-7, April 2001 (2001-04), pages 501-506, XP002403638 ISSN: 1525-7770 * |
See also references of WO2004097003A2 * |
VANDEYAR M A ET AL: "A simple and rapid method for the selection of oligodeoxynucleotide-directed mutants." GENE. 15 MAY 1988, vol. 65, no. 1, 15 May 1988 (1988-05-15), pages 129-133, XP002404235 ISSN: 0378-1119 * |
Also Published As
Publication number | Publication date |
---|---|
CA2521520A1 (en) | 2004-11-11 |
WO2004097003A2 (en) | 2004-11-11 |
JP2006525023A (en) | 2006-11-09 |
EP1618187A4 (en) | 2006-12-20 |
US20050239087A1 (en) | 2005-10-27 |
WO2004097003A3 (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001268725B2 (en) | Multiply-primed amplification of nucleic acid sequences | |
AU2001268725A1 (en) | Multiply-primed amplification of nucleic acid sequences | |
KR100682576B1 (en) | Method for amplifying nucleic acid sequence | |
US8673567B2 (en) | Method and kit for nucleic acid sequence detection | |
US6811986B2 (en) | 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms | |
US7309571B2 (en) | Amplification of self-ligated, circularized cDNA for expression profiling | |
EP1299557B1 (en) | Signal amplification with lollipop probes | |
CN109251965B (en) | PCR buffer composition for enhancing DNA polymerase activity with increased gene mutation specificity | |
AU2001271722A1 (en) | Signal amplification with lollipop probes | |
WO2005100594A1 (en) | A method for selectively detecting subsets of nucleic acid molecules | |
US20050239087A1 (en) | Multiply-primed amplification of nucleic acid sequences | |
EP2126133B1 (en) | Multiply-primed amplification of circular nucleic acid sequences | |
CA2266847A1 (en) | Compositions and methods for enhancing hybridization specificity | |
EP1583840A2 (en) | Target-dependent transcription | |
WO2006005055A2 (en) | Methods reaction mixtures and kits for ligating polynucleotides | |
AU2004205118A1 (en) | Method for amplifying nucleic acid sequence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051011 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12Q 1/68 20060101AFI20060327BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GE HEALTHCARE BIO-SCIENCES CORP. |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20061120 |
|
17Q | First examination report despatched |
Effective date: 20070316 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20110609 |